COLLEEN FULLERTON: Open Payments
NPI 1528139730 · PROVIDENCE, RI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,573 in 64 payments from 12 companies in 2025. Trend: 2023 $2,631 · 2024 $2,242 · 2025 $1,573
Food & beverage: $1,573
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $488 |
| Janssen Biotech, Inc. | 3 | $274 |
| Ardelyx, Inc. | 8 | $150 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $136 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $108 |
| Ipsen Biopharmaceuticals, Inc | 1 | $103 |
| Gilead Sciences, Inc. | 4 | $94 |
| Intercept Pharmaceuticals, Inc. | 3 | $79 |
| Braintree Laboratories, Inc. | 3 | $67 |
| Medtronic, Inc. | 1 | $34 |
Products named: TREMFYA, CREON, IBSRELA, LINZESS, XIFAXAN, IQIRVO, ENTYVIO, OCALIVA.
Industry payments across RI — which companies pay providers there.
